

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: <b>Domány <i>et al.</i></b>	Confirmation No.: 4047
Application No.: 10/761,940	Art Unit: 1625
Filed: January 21, 2004	Examiner: Chang, Celia C.
For: <b>Piperidine Derivatives as NMDA Receptor Antagonists</b>	Atty. Docket: 1000546-0003

**Amendment and Reply Under 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

*Mail Stop: Amendment  
Art Unit 1625*

Sir:

In reply to the Office Action dated December 26, 2006, Applicants submit the following Reply. This Reply is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or other fees are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 50-3626.